These projects meet the principles outlined by the Department of Health and the ABPI (Association of the British Pharmaceutical Industry) and enable us to work closely with the NHS which is at the core of our patient centred strategy.
The project objectives put patient care right at their centre and pooled skills, experience and / or resources from the NHS and industry are used to jointly develop and implement the initiative. Joint working really illustrates the way that Teva is able to be flexible and look at the needs of a particular patient population.
Additional information
These documents and the activities they describe were created and certified as compliant with all codes, regulations and laws in force during the period of time from their creation to completion. By accessing the documents within this archive library the reader acknowledges and accepts any differences that may exist between the standards and practices required today and those that were adhered to at the time when the activities and documents were certified.
A Joint Working Case Study between Ashford CCG and Teva UK Limited
Download the joint working case study >
This is an example of how Ashford Clinical Commissioning Group (CCG) worked on a local joint working project with Teva UK Limited to deliver an MUR support programme, which included inhaler technique training, Medicine Use Review (MUR) training and other support services.
Long-term conditions, including respiratory illness and asthma, featured in Ashford CCG’s 2013-14 plans and priorities.
Medicines Use Reviews (MURs) provide pharmacists with the opportunity to influence patients’ knowledge and adherence to treatment.
The joint working project was envisaged to help support and train surgery healthcare professionals (HCPs) and community pharmacists on inhaler technique to a consistently high standard.
The objectives of this joint working project were:
In order to achieve these outcomes, Ashford CCG worked in collaboration with Teva UK Limited as they provided:
Both Ashford CCG and Teva UK Limited abided by the relevant regulatory bodies and guidance, including the ABPI Code of Practice.
Following the initial mailing to patients, the response to the MUR invitation was an attendance rate of 5% (24 patients).
With agreement from the practice and pharmacies taking part in the project it was agreed that an additional mailing would take place with the objective of increasing attendance. The final attendance was 6% (33 patients).
At the time of MUR, the pharmacist identified the following:
This project demonstrated a successful collaborative approach to address a significant issue facing the local health economy. A consideration for future projects will be to ensure greater engagement with pharmacists to improve both patient recruitment and project outcomes.
Joint working between Teva UK Limited and the NHS must be for the benefit of patients or the NHS and preserve patient care1
_______________________________________________________________________________
References
[1] Department of Health. Best practice guidance for joint working between the NHS and the pharmaceutical industry, 1 February 2008
A Joint Working case study between NHS Bristol and Teva UK Limited
Download the joint working case study >
NHS Bristol identified there were 79,794 emergency hospital admissions for asthma in the UK in 2008-09 with an estimated 75% being avoidable.1 During that time, around 600 people were admitted to hospital as a result of their asthma, with four deaths in Bristol alone.
NHS Bristol wanted to improve asthma management to reduce asthma hospital admissions.
Previous audits had identified:
The objectives for the project were aligned to QIPP:
Reduction in hospital admissions
There was a 19.46% reduction in asthma admissions in 2011/12 in Bristol (n=56) compared to the previous year. Practices participating in the IMPACT programme accounted for 54.7% of this (n=13).
Results from the IMPACT service patient evaluation showed that patients felt more confident in managing their asthma and that they were using their inhalers correctly following a structured asthma review.
Question (‘Strongly agree’ or ‘Agree’)
In alignment with QIPP, NHS Bristol succeeded in improving asthma management to reduce (prevent) asthma hospital admissions. Benefits included:
Joint Working between Teva UK Limited and the NHS must be for the benefit of patients or the NHS and preserve patient care.8
_______________________________________________________________________________
References
[1] Asthma UK for Journalists: Key facts and stats: www.asthma.uk.org (Viewed June 2012).
[2] Thorax 2008; 63(Supplement 4):iv1- iv121. [Accessed June 2012] Available from: http://dx.doi.org/http://www.sign.ac.uk/guidelines/ fulltext/101/index.html.
[3] Nursing and Midwifery Council. Standards of conduct, performance and ethics for nurses and midwives. [Last Accessed: June 2012]; Available from: http://www.nmc-uk.org/aArticle.aspx?ArticleID=3056.
[4] The Association of the British Pharmaceutical Industry (ABPI) Code of Practice (2012).[Last Accessed: June 2012]; Available from: http://www.abpi.org.uk/publications/pdfs/pmpca_code2011.pdf
[5] The Caldicott Committee. Report on the Review of Patient-Identifiable Information. 1997 [Last Accessed: May 2012]; Available from: http://www.wales.nhs.uk/sites3/Documents/783/DH%5F4068404%5B1%5D.pdf.
[6] UK Data Protection Act. 1998 [Last Accessed: June 2012]; Available from: http://www.opsi.gov.uk/acts/acts1998/ukpga_19980029_en_1.
[8] Department of Health. Best practice guidance for Joint Working between the NHS and the pharmaceutical industry, 1 February 2008.
A Joint Working Case Study between WHCC and Teva UK Limited
Download the joint working case study >
This is a case study of how Wirral Health Commissioning Consortium (WHCC) worked in a local joint working initiative with the Integrated Healthcare Manager from Teva UK Limited to improve asthma outcomes in registered practices.
According to the Practice Level Register as of the 1st April 2012, WHCC had 10,897 patients with a diagnosis of asthma. The average prevalence rate is 6.6% compared to a UK average of 5.6%. WHCC identified that over the last three years the annual average number of non-elective emergency admissions for WHCC was 255, with an approximate cost of £379,000.
WHCC wanted to explore innovations and best practice with the aim of improving asthma outcomes for patients registered to the WHCC practices.
This real-life case study compares the results of the baseline audit to the outcomes of the 12 month re-audit.
The objectives of this joint working initiative were:
In order to achieve these outcomes, WHCC worked in collaboration with Teva UK Limited as they provided:
Both the WHCC and Teva UK Limited abided by the relevant regulatory bodies and guidance, including the ABPI Code of Practice.
Baseline audit:
12 month re-audit:
In WHCC, from the 14 practices included in the re-audit, the prevalence of asthma was 7.10% compared to 6.67% prevalence at the time of the original audit.
(a) Reduction in hospital admissions and associated costs
(b) Total costs for WHCC inpatient admissions for asthma
(c) Other patient outcomes observed
(d) Positive feedback from practice nurses
This project demonstrated a successful collaborative approach to address a significant issue facing the local health economy.
oint working between Teva UK Limited and the NHS must be for the benefit of patients or the NHS and preserve patient care1
_______________________________________________________________________________
References
[1] Department of Health. Best practice guidance for joint working between the NHS and the pharmaceutical industry, 1 February 2008
A Joint Working Case Study Stockport Clinical Commissioning Group (CCG) and Teva UK Limited
Download the joint working case study >
This is a case study of how Stockport CCG participated in a local joint working initiative with the Project Group from Teva UK Limited to explore how cascading advanced knowledge of inhaler technique to healthcare professionals (HCPs) could help patients recognise their type of inhaler device and associated technique.
Research
Asthma and COPD are long term conditions that feature prominently in Domain 2 of the NHS Outcomes Framework 2013/2014 and National COPD and Asthma Outcomes Strategy, Department of Health.
Research has shown that:
It has been demonstrated in several areas of the UK that engaging patients that use inhalers in Medicines Use Reviews and providing HCPs with the right skills and tools to deliver these can lead to an improvement in outcomes for patients.
Whilst prescribing might be optimal, if a patient cannot use their inhaler properly, there is a risk that their lack of control will result in further treatment interventions, such as unnecessarily high inhaled corticosteroid (ICS) doses. Patients with poor control of their asthma and COPD are more likely to have exacerbations and be admitted to hospital as a consequence.
The cost of medicines waste resulting from suboptimal inhaler use is considerable. Poor control may lead to extra cost with regard to GP and nurse appointments and hospital admissions.
For these reasons Stockport CCG identified inhaler technique as an area of focus in 2014 and 2015. A part of this focus stated a desire to leave a legacy of improved knowledge relating to Inhaler Technique across general practice in Stockport CCG and cascade this knowledge to patients via primary care healthcare professionals.
Recognising this opportunity, the objectives of this joint working initiative in Stockport CCG were to:
The joint working group was interested to see if and how this approach could reduce and prevent emergency hospital admissions amongst asthma and COPD patients.
The success of the project in meeting the desired outcomes was measured in the following ways:
In order to achieve these outcomes, Stockport CCG worked in collaboration with Teva UK Limited as they provided:
Both Stockport CCG and Teva UK Limited abided by the relevant regulatory bodies and guidance, including the ABPI Code of Practice.3
The project was split into three distinct phases.
The project succeeded in improving respiratory care by raising the importance of inhaler device technique in a consistent and informed way with healthcare professionals and patients.
Prior to the HCP inhaler technique training:
45 healthcare professionals were trained. After attending the HCP training on inhaler technique, the following percentage of healthcare professionals felt the following:
11 patients reported back on the training. After receiving training from an HCP on inhaler technique as part of the project:
The aim of recruiting more than 25 practices for the project was missed, with only 6 practices being recruited for reasons outside the scope of this project. However, those 6 practices were able to demonstrate patient outcomes.
This project demonstrated a successful collaborative approach to address a significant issue facing the local health economy.
The project improved respiratory care through improving the knowledge of healthcare professionals in relation to the types of inhaler devices available and the associated inhaler technique.
This improved the skills of the healthcare professionals so that they are able to support patients suffering with asthma.
Joint working between Teva UK Limited and the NHS must be for the benefit of patients or the NHS and preserve patient care3
_______________________________________________________________________________
References
[1] Van Ganse et al Factors affecting adherence to asthma treatment: patient and physician perspectives. Prim Care Resp J 2003;12(2):46-51
[2] Baverstock M, et al. Do Healthcare Professionals have sufficient knowledge of Inhaler Techniques in order to educate their patients effectively in their use? Thorax 2010;65:pA117[poster]
[3] Department of Health. Best practice guidance for joint working between the NHS and the pharmaceutical industry, 1 February 2008
A Joint Working case study between Gloucester Clinical Commissioning Group (CCG) and Teva UK Limited
Download the Teva & NHS Joint Working case study >
This is a case study of how Gloucestershire CCG worked in a local joint working initiative with the Project Group from Teva UK Limited to improve asthma outcomes in relevant practices.
Asthma and Chronic Obstructive Pulmonary Disease (COPD) are long term conditions that feature prominently in Domain 2 of the NHS Outcomes Framework 2013/2014 and National COPD and Asthma Outcomes Strategy, Department of Health.
Locally in 2011, NHS Gloucestershire - now Gloucestershire Clinical Commissioning Group (CCG) - saw an increase in number of hospital admissions per patient and number of patients admitted for asthma ICD-10 codes.
The CCG project lead approached Teva UK Limited to determine if they would be interested in working collaboratively on rolling out the Advance Inhaler Training module that had been recently accredited by the WCCPE at Cardiff University, as it focuses on the importance of inhaler technique which they believed was vital in order to gain control of the increase in admissions related to asthma.
Gloucestershire then had around 41,000 diagnosed patients with asthma and around 10,000 diagnosed with COPD, spending approximately £14m annually on respiratory care. However, it was recognised that:
Gloucestershire CCG believed that having a number of accredited AIT trainers locally would have a positive effect on the integrated approach that they are aiming to achieve.
Through the formation of an asthma project group, there was a desire to run an AIT course to train 14 healthcare professionals (HCPs) from Gloucestershire CCG. These were made up of practice support pharmacists (PSPs) and practice nurses that had an interest in respiratory, along with secondary care respiratory pharmacists that had an interest in asthma.
Once the relevant HCPs had been trained and accredited via WCCPE, they were tasked with up-skilling other HCPs from the 86 practices, 113 community pharmacies and also the hospitals within Gloucestershire CCG.
The project aimed to improve respiratory care by raising the importance of device technique in a consistent and informed way with healthcare professionals and patients.
Recognising this opportunity, the objectives of this joint working initiative in Gloucestershire CCG was to:
Joint Working Initiative with Teva UK Limited
In order to achieve these outcomes, Gloucestershire CCG worked in collaboration with
Teva UK Limited as they provided:
Both Gloucestershire CCG and Teva UK Limited abided by the relevant regulatory bodies and guidance, including the ABPI Code of Practice and guidance.
The project was split into three distinct phases.
The project succeeded in improving respiratory care by raising the importance of device technique in a consistent and informed way with healthcare professionals and patients.
(a) Over 900 healthcare professionals received Advanced Inhaler Training and consistent training around device technique
(b) Positive feedback was received from healthcare professionals of the Advanced Inhaler Training
Feedback was received from patients who participated
(c) Impact on hospital admissions and associated costs
This project demonstrated a successful collaborative approach to address a significant issue facing the local health economy. Factors beyond the scope of this project may have impacted on the project results achieved.
The project improved respiratory care by raising the importance of device technique in a consistent and informed way with healthcare professionals and patients.
Joint working between Teva UK Limited and the NHS must be for the benefit of patients or the NHS and preserve patient care.4
_______________________________________________________________________________
References
[1] Restepo et al, Int of Chron Pulmon Dis 2008; 3(3): 371-384
[2] Garcia-Aymerich et al, Eur Respir J 2000; 16: 1037-1042
[3] Baverstock M, et al. Do Healthcare Professionals have sufficient knowledge of Inhaler Techniques in order to educate their patients effectively in their use? Thorax 2010;65:pA117[poster]
[4] Department of Health. Best practice guidance for joint working between the NHS and the pharmaceutical industry, 1 February 2008